ETV6 antibody
- Known as:
- ETV6 (anti-)
- Catalog number:
- orb39610
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ETV6 antibody
Related genes to: ETV6 antibody
- Gene:
- ETV6 NIH gene
- Name:
- ETS variant 6
- Previous symbol:
- -
- Synonyms:
- TEL
- Chromosome:
- 12p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1995-11-28
- Date modifiied:
- 2019-04-23
Related products to: ETV6 antibody
Related articles to: ETV6 antibody
- Acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy, with the majority of cases being of B-cell origin. While many patients respond favorably to therapy, a subset experiences early relapse or poor outcomes, underscoring the critical need for reliable prognostic biomarkers. This study investigated the significance of CD123 expression in diagnosing the disease, evaluating therapeutic efficacy, and predicting prognosis in pediatric B-cell ALL (B-ALL). - Source: PubMed
Publication date: 2026/08/12
Li ZhengChen QinfaZhou ZhiyongHe Fei - Soft tissue sarcomas (STSs) are a heterogeneous group of rare mesenchymal malignancies with overlapping morphological and immunohistochemical features, often making definitive diagnosis challenging. Recent advances in next-generation sequencing (NGS) have enabled the identification of recurrent molecular alterations that contribute to tumor classification, prognostic stratification, and precision oncology approaches. This retrospective study aimed to evaluate the diagnostic and clinical impact of molecular profiling in pediatric soft tissue sarcomas using the Oncomine Childhood Cancer Research Assay (OCCRA) panel. Fifty-five frozen tumor samples representing 24 distinct soft tissue sarcoma subtypes were obtained from the Pediatric Oncology Institute -IOP/GRAACC/UNIFESP Biobank (B-053). Molecular analysis was performed using NGS to identify gene fusions, single nucleotide variants (SNVs), copy number variations (CNVs), and insertions/deletions (InDels). Clinically relevant molecular alterations were identified in 70% (37/55) of cases, including 18 fusion transcripts, 13 SNVs, 8 CNVs, and 6 InDels. Recurrent and diagnostically relevant alterations included ::, ::, :, ::, ::, ::, ::, :: and :: fusions, as well as amplifications involving , , , , , and . Pathogenic variants affecting genes involved in tumor suppression and chromatin remodeling, including , , , , , and , were also detected. Importantly, molecular profiling had significant diagnostic impact in several histologically ambiguous tumors, enabling molecular reclassification and refinement of previously inconclusive or inaccurate pathological diagnoses. In multiple cases, NGS transformed descriptive histopathological interpretations into genetically defined sarcoma entities, including -rearranged spindle cell neoplasms, -rearranged sarcomas, synovial sarcoma, low-grade fibromyxoid sarcoma, and clear cell sarcoma. Furthermore, the identification of actionable alterations highlighted potential opportunities for targeted therapies and precision medicine approaches. Our findings demonstrate that comprehensive molecular profiling significantly enhances diagnostic accuracy in pediatric soft tissue sarcomas, particularly in morphologically challenging cases. The integration of NGS into routine sarcoma diagnostics enables biologically informed tumor classification and supports personalized therapeutic strategies. - Source: PubMed
Publication date: 2026/08/12
Tesser-Gamba FrancineMendes Thais BiudeLima Fernanda TeresaAbib Simone de Campos VieiraCaran Eliana Maria MonteiroToledo Silvia Regina Caminada de - Accurate identification of pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients at increased risk of relapse remains a major clinical challenge, as relapse occurs in 10-20% of cases, including patients initially classified as low- or intermediate-risk. This study aimed to identify clinical, genomic, and measurable residual disease (MRD) related predictors of relapse in pediatric B-ALL. - Source: PubMed
Publication date: 2026/08/14
Prats-Martín ConcepciónPérez Ortega LauraMolinos Quintana ÁguedaRibera JordiChiclana Rodríguez BeatrizCaballero-Velázquez TeresaCarrillo Cruz EstrellaAndrade-Ruiz Henry AntonioGarrastazul Sánchez María PazMadrigal Toscano María DoloresSolé Rodríguez MaríaGómez Rosa MarinaPérez-Simón José AntonioMorales-Camacho Rosario M - To evaluate differences in radiological phenotypes between B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL) in pediatric patients and to assess their correlation with specific genetic alterations. - Source: PubMed
Publication date: 2026/08/21
Rocka AgataSuchcicka MariaWoźniak Magdalena MariaLejman Monika - Aberrant DNA methylation is a hallmark of acute myeloid leukemia (AML) and contributes to leukemogenesis, treatment response, and clinical heterogeneity. While genome-wide methylation studies have identified prognostic methylation signatures, the impact of DNA methylation within pharmacologic pathways and AML-relevant disease genes remains incompletely understood. We investigated the association of DNA methylation in genes of pharmacokinetic/pharmacodynamic (PK/PD) pathways of drugs used to treat AML and in myeloid leukemia-related genes with treatment outcomes in pediatric AML. - Source: PubMed
Publication date: 2026/07/31
Alshameri NaifahMarchi FranciscoCao XueyuanRubnitz Jeffrey ERibeiro Raul CMeshinchi SoheilPounds Stanley BLamba Jatinder K